ADPKD Treatment Report

www.ADPKDTreatmentReport.com

Phase 2

Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease

https://clinicaltrials.gov/ct2/show/NCT02656017?type=Intr

https://clinicaltrials.gov/ct2/show/NCT02656017?type=Intr&cond=ADPKD&phase=01245&lupd_s=09%2F14%2F2020&lupd_d=1&sort=nwst

STUDY TITLE:
Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease

STUDY DESCRIPTION:
Condition :   Polycystic Kidney, Autosomal Dominant

Interventions :   Drug: Metformin;   Other: Placebo

Sponsors :   Kyongtae Ty Bae, M.D., Ph.D.;   Tufts Medical Center;   University of Maryland, Baltimore;   University of Southern California;   United States Department of Defense

Active, not recruiting

CLINICALTRIALS.GOV ID:
NCT02656017

FIRST POSTED:
Thu, 14 Jan 2016 12:00:00 EST

LAST UPDATE POSTED:
09/15/20 06:51AM

STUDY LINK:
https://clinicaltrials.gov/ct2/show/NCT02656017?type=Intr&cond=ADPKD&phase=01245&lupd_s=09%2F14%2F2020&lupd_d=1&sort=nwst

NOTES:

A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients

https://clinicaltrials.gov/ct2/show/NCT03523728?type=Intr&cond=ADPKD&phase=01245&lupd_s=09%2F13%2F2020&lupd_d=1&sort=nwst

STUDY TITLE:
A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients

STUDY DESCRIPTION:
Condition :   Polycystic Kidney, Autosomal Dominant

Interventions :   Drug: Venglustat GZ402671;   Drug: Placebo

Sponsor :   Genzyme, a Sanofi Company

Recruiting

CLINICALTRIALS.GOV ID:
NCT03523728

FIRST POSTED:
Mon, 14 May 2018 12:00:00 EDT

LAST UPDATE POSTED:
09/14/20 07:12AM

STUDY LINK:
https://clinicaltrials.gov/ct2/show/NCT03523728?type=Intr&cond=ADPKD&phase=01245&lupd_s=09%2F13%2F2020&lupd_d=1&sort=nwst

NOTES:

Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD

https://clinicaltrials.gov/ct2/show/NCT03203642

Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD

Study Type : Interventional (Clinical Trial)
Actual Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-blind Randomized Parallel Group Study of the Efficacy and Safety of Tesevatinib in Subjects With Autosomal Dominant Polycystic Kidney Disease
Actual Study Start Date : August 9, 2017
Estimated Primary Completion Date : January 31, 2022
Estimated Study Completion Date : January 31, 2022

Pravastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD-SAT)

https://clinicaltrials.gov/ct2/show/NCT04284657

Pravastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD-SAT)

Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pravastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease
Actual Study Start Date : January 30, 2019
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : December 31, 2020

Back to top